250 related articles for article (PubMed ID: 16985092)
41. Phosphodiesterase 4 inhibition of beta2-integrin adhesion caused by leukotriene B4 and TNF-alpha in human neutrophils.
Meliton AY; Muñoz NM; Lambertino A; Boetticher E; Learoyd J; Zhu X; Leff AR
Eur Respir J; 2006 Nov; 28(5):920-8. PubMed ID: 16807266
[TBL] [Abstract][Full Text] [Related]
42. COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1.
Celli B
Chest; 2006 Jan; 129(1):5-6. PubMed ID: 16424403
[No Abstract] [Full Text] [Related]
43. Phosphodiesterase 4 inhibitors modulate beta2-adrenoceptor agonist-induced human airway hyperresponsiveness.
Faisy C; Risse PA; Naline E; Guerot E; Fagon JY; Devillier P; Advenier C
Life Sci; 2006 Oct; 79(20):1929-35. PubMed ID: 16820175
[TBL] [Abstract][Full Text] [Related]
44. Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.
Pruniaux MP; Lagente V; Ouaged M; Bertin B; Moreau F; Julien-Larose C; Rocher MN; Leportier C; Martin B; Bouget A; Dubuit JP; Burnouf C; Doherty AM; Bertrand CP
Fundam Clin Pharmacol; 2010 Feb; 24(1):73-82. PubMed ID: 19650853
[TBL] [Abstract][Full Text] [Related]
45. Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes.
Bäumer W; Kietzmann M
Vet Dermatol; 2007 Apr; 18(2):107-14. PubMed ID: 17355425
[TBL] [Abstract][Full Text] [Related]
46. Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD.
Jeffery P
Pulm Pharmacol Ther; 2005; 18(1):9-17. PubMed ID: 15607122
[TBL] [Abstract][Full Text] [Related]
47. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC
J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386
[TBL] [Abstract][Full Text] [Related]
48. AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis.
Bäumer W; Gorr G; Hoppmann J; Ehinger AM; Rundfeldt C; Kietzmann M
J Pharm Pharmacol; 2003 Aug; 55(8):1107-14. PubMed ID: 12956900
[TBL] [Abstract][Full Text] [Related]
49. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
Banner KH; Trevethick MA
Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712
[TBL] [Abstract][Full Text] [Related]
50. Phosphodiesterase 4 inhibitors: antiinflammatory therapy for chronic obstructive pulmonary disease at last?
Kerstjens HA; Timens W
Am J Respir Crit Care Med; 2003 Oct; 168(8):914-5. PubMed ID: 14555456
[No Abstract] [Full Text] [Related]
51. CC-10004 .
Khobzaoui M; Gutke HJ; Burnet M
Curr Opin Investig Drugs; 2005 May; 6(5):518-25. PubMed ID: 15912967
[TBL] [Abstract][Full Text] [Related]
52. AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).
Gutke HJ; Guse JH; Khobzaoui M; Renukappa-Gutke T; Burnet M
Curr Opin Investig Drugs; 2005 Nov; 6(11):1149-58. PubMed ID: 16312137
[TBL] [Abstract][Full Text] [Related]
53. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease.
Soto FJ; Hanania NA
Curr Opin Pulm Med; 2005 Mar; 11(2):129-34. PubMed ID: 15699784
[TBL] [Abstract][Full Text] [Related]
54. The next generation of PDE4 inhibitors.
Huang Z; Ducharme Y; Macdonald D; Robichaud A
Curr Opin Chem Biol; 2001 Aug; 5(4):432-8. PubMed ID: 11470607
[TBL] [Abstract][Full Text] [Related]
55. Pharmacology of a novel, orally active PDE4 inhibitor.
Dastidar SG; Ray A; Shirumalla R; Rajagopal D; Chaudhary S; Nanda K; Sharma P; Seth MK; Balachandran S; Gupta N; Palle V
Pharmacology; 2009; 83(5):275-86. PubMed ID: 19321962
[TBL] [Abstract][Full Text] [Related]
56. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration.
Kuss H; Hoefgen N; Johanssen S; Kronbach T; Rundfeldt C
J Pharmacol Exp Ther; 2003 Oct; 307(1):373-85. PubMed ID: 12944497
[TBL] [Abstract][Full Text] [Related]
57. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
58. Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol.
Murdoch RD; Cowley H; Kelly J; Higgins R; Webber D
Pulm Pharmacol Ther; 2002; 15(6):521-7. PubMed ID: 12493339
[TBL] [Abstract][Full Text] [Related]
59. Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers.
Murdoch RD; Zussman B; Schofield JP; Webber DM
J Clin Pharmacol; 2004 Sep; 44(9):1046-53. PubMed ID: 15317832
[TBL] [Abstract][Full Text] [Related]
60. Synthesis, biological evaluation and molecular modelling studies on benzothiadiazine derivatives as PDE4 selective inhibitors.
Tait A; Luppi A; Hatzelmann A; Fossa P; Mosti L
Bioorg Med Chem; 2005 Feb; 13(4):1393-402. PubMed ID: 15670947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
